Analysis of mTOR-related Signaling Pathways in Stroke

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase composed of two protein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTOR is highly conserved and is the center of multiple signaling pathways, coordinating important cellular processes such as cell growth and metabolism. Furthermore, mTOR is particularly abundant in the brain, and its dysfunction profoundly affects the central nervous system (CNS). During ischemic stroke, the mTOR signaling pathway can regulate post-ischemic inflammation and autophagy processes through a variety of signaling pathways. Since both mTORC1 and mTORC2 regulate important cellular functions, they are promising targets for stroke therapy.

Fig. 1. mTORC1 and mTORC2 are interesting targets for stroke therapy. Fig. 1. mTOR: hitting the bull's eye for enhancing neurogenesis after cerebral ischemia. (Gao et al., 2023)

Our Services

Ace Therapeutics provides comprehensive services for analyzing mTOR-related signaling pathways and developing stroke drugs targeting the mTOR pathway. Our team of highly skilled experts has many years of experience in the field and is dedicated to analyzing mTOR-related signaling pathways in ischemia and hypoxia at the tissue and cellular levels. In addition, we can help clients develop stroke drugs that target the mTOR pathway.

In Vitro Analysis of mTOR-related Signaling Pathways in Stroke

We use in vitro models of ischemic stroke to study the effects of hypoxia and glucose deprivation (OGD) on mTOR-related signaling pathways. By performing OGD on primary cultured neurons or glial cells, we can precisely control the duration of ischemic exposure and study the molecular changes in different neuronal cell types at different time points.

In Vivo Analysis of mTOR-related Signaling Pathways in Stroke

Our researchers use animal models of ischemic stroke to help clients study mTOR-related signaling pathways. We can measure mTOR activity at the tissue level as well as detect the expression levels of mTOR-related molecules.

Upstream regulatory pathways of mTORC
  • PI3K/Akt/mTORC1 pathway: Nerve growth factor (NGF), brain-derived growth factor (BDNF), vascular endothelial growth factor (VEGF), insulin, insulin-like growth factor-1 (IGF-1) and neurotrophins (NT-1, -3 and -4).
  • MAPK-mTORC1 pathway
  • AMPK-mTORC1 pathway
Downstream targets of mTORC
  • mTORC1 downstream targets: P70S6K, 4EBPs, SREBP1-2, ULK1, and UVRAG
  • mTORC2 downstream targets: Akt, PKC, and SGK1

Our Advantages

  • We can perform a detailed and precise analysis of mTOR-related signaling pathways to ensure the highest quality data for clients.
  • Whether using primary cultured cells for in vitro studies or animal models for in vivo analysis, we design customized experimental protocols to address specific research questions.
  • Our team includes neuroscientists, molecular biologists, bioinformaticians, and statisticians. They work closely together to provide a fully integrated analysis of mTOR-related signaling pathways in stroke.
  • Our efficient workflow and streamlined processes allow us to deliver analyzed data and comprehensive reports within agreed-upon timelines.

With our expertise, state-of-the-art facilities, and collaborative approach, Ace Therapeutics is committed to helping clients evaluate the neuroprotective and therapeutic potential of targeting mTOR pathway in ischemic stroke. We strive to meet the needs of clients by providing them with valuable data to advance their research goals. If you are interested in our services, please do not hesitate to contact us!

  1. Gao, J., et al. (2023). mTOR (mammalian target of rapamycin): hitting the bull's eye for enhancing neurogenesis after cerebral ischemia? Stroke, 54(1), 279-285.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket